The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy

Wiener Klinische Wochenschrift

Volumn 111, Issue 17, 1999, Pages 728-737

  Kieseier, Bernd C ^a   Archelos, Juan J ^a   Storch, Maria ^a   Gold, Ralf ^b   Hartung, Hans Peter ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Autoimmunity; Axonal loss; Demyelination; Immunotherapy; Multiple sclerosis

Indexed keywords

AUTOIMMUNITY; DEMYELINATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; PATHOPHYSIOLOGY; REVIEW; WHITE MATTER;

AUTOIMMUNITY; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; VACCINES;

EID: 0033578973     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Birnbaum G, Antel J (1998) The immunology of multiple sclerosis. In: Antel J, Birnbaum G, Hartung H-P (eds) Clinical immunology. Blackwell, Malden, pp 105-115
2. Raine CS (1997) The neuropathology of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW (eds) Multiple sclerosis: clinical and pathogenetic basis. Chapman & Hall, London, pp 151-171
3. Lassmann H, Zimprich F, Rössler K, Vass K (1991) Inflammation in the nervous system. Basic mechanisms and immunological concepts. Rev Neurol (Paris) 147: 763-781
4. Hauser SL, Fleischnick E, Weiner HL, Marcus D, Awdek Z, Yunis EJ, Alper CA (1989) Extended major histocompatibility complex haplotypes in patients with multiple sclerosis. Neurology 39: 275-277
5. Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120: 865-916
6. Bashir K, Whitaker JN (1998) Current immunotherapy in multiple sclerosis. Immunol Cell Biol 76: 55-64
7. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C (1994) Animal models. Ann Neurol 36: S47-S53
8. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH (1995) B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718
9. Brocke S, Hausmann S, Steinman L, Wucherpfennig KW (1998) Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Semin Immunol 10: 57-67
10. Hartung HP (1995) Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 8: 191-199
11. Hartung HP (1993) Immune-mediated demyelination. Ann Neurol 33: 563-567
12. Cannella B, Raine C (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 36: 561-572
13. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL (1986) Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 19: 578-587
14. Romagnani S (1997) The Th1/Th2 paradigm. Immunol Today 18: 263-265
15. Benveniste EN (1997) Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75: 165-173
16. Bo L, Dawson TM, Wesselingh S, Sverre M, Choi S, Kong PA, Hanley D, Trapp BD (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36: 778-786
17. Brosnan CF, Battistini L, Raine CS, Dickson DW, Cusadevall A, Lee SC (1994) Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 16: 152-161
18. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285
19. Matis LA (1990) The molecular basis of T-cell specificity. Annu Rev Immunol 8: 65-82
20. Van Parijs L, Abbas AK (1998) Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280: 243-248
21. Hohlfeld R, Meinl E, Weber F, Zipp F, Schmidt S, Sotgiu S, Goebles N, Voltz R, Spuler S, Iglesias A, Wekerle H (1995) The role of autoimmune T lymhocytes in the pathogenesis of multiple sclerosis. Neurology 45: S33-S38
22. Battistini L, Selmaj K, Kowal C, Ohmen J, Modlin RL, Raine CS, Brosnan CF (1995) Multiple sclerosis: limited diversity of the V delta 2-J delta 3 T-cell receptor in chronic active lesions. Ann Neurol 37: 198-203
23. Meinl E, Weber F, Drexler K, Morelle C, Ott M, Saruhan-Direskeneli G, Goebels N, Ertl B, Jechart G, Giegerich G, Wekerle H (1993) Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 92: 2633-2643
24. Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, Wekerle H (1990) Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40: 1770-1776
25. Wallström E, Khademi M, Andersson M, Weissert R, Linington C, Olsson T (1998) Increased reactivity of myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR28(15)+ multiple sclerosis. Eur J Immunol 28: 3329-3335
26. Kojima K, Berger T, Lassmann H, Hinze-Selch D, Zhang Y, Gehrmann J, Reske K, Wekerle H, Linington C (1994) Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med 180: 817-829
27. Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal-Malefyt R, Wekerle H, Hohlfeld R (1997) Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 120: 1437-1445
28. Hartung HP, Rieckmann P (1997) Pathogenesis of immune-mediated demyelination in the CNS. J Neural Transm [Suppl 50]: 173-181
29. Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD (1998) The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 164:63-72
30. Tuohy VK, Yu M, Yin L, Kawczak JA, Johnson JM, Mathisen PM, Weinstock-Guttman B, Kinkel RP (1998) The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 164: 93-100
31. Bianchi E, Bender JR, Blasi F, Pardi R (1997) Through and beyond the wall: late steps in leukocytes transendothelial migration. Immunol Today 18: 586-591
32. Svenningsson A, Stemme S (1994) Cell adhesion molecules in multiple sclerosis. CNS Drugs 2: 87-95
33. Karlik SJ, Hyduk SJ, Rice GPA (1998) Adhesion molecules: an intriguing therapeutic target in MS. Int MS J 4: 54-61
34. Archelos JJ, Jung S, Rinner W, Lassmann H, Miyasaka M, Hartung HP (1998) Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. J Neurol Sci 159: 127-134
35. Gearing AJH, Newman W (1993) Circulating adhesion molecules. Immunol Today 14: 506-512
36. Ward SG, Bacon K, Westwick J (1998) Chemokines and T lymphocytes: more than an attraction. Immunity 9: 1-11
37. Ransohoff RM, Glabinski A, Tani M (1996) Chemokines in immune-mediated inflammation of the central nervous system. Cytokine Growth Factor Rev 7: 35-46
38. Luster AD (1998) Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445
39. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC (1998) Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279: 381-384
40. Glabinski AR, Tani M, Stricter RM, Tuohy VK, Ransohoff RM (1997) Synchronous synthesis of alpha-and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 150: 617-630
41. Mijagishi R, Kikuchi S, Takayama C, Inoue Y, Tashiro K (1997) Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol 77: 17-26
42. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K (1995) Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 129: 223-227
43. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103: 807-815
44. Woessner Jr JF (1994) The family of matrix metalloproteinases. Ann N Y Acad Sci 732: 11-21
45. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21: 75-80
46. Hartung H-P, Kieseier BC (1996) Targets for the therapeutic action of interferon-b in multiple sclerosis (Editorial). Ann Neurol 40: 825-826
47. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GMA, Schweitzer T, Gearing AJH, Hartung H-P (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121: 159-166
48. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55: 1194-1204
49. Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55: 300-309
50. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL (1995) T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154: 4379-4389
51. Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40: 846-852
52. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Wiliams G, Yong VW (1996) Interferon b-lb decreases the migration of T lymphocytes in vitro: effects on matrix-metalloproteinase-9. Ann Neurol 40: 853-863
53. Cuzner ML, Davison AN, Rudge P (1978) Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 4: 337-344
54. Gijbels K, Masure S, Carton H, Opdenakker G (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol 41: 29-34
55. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46: 1626-1632
56. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201: 223-226
57. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Wooley K (1994) Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature 370: 555-557
58. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA (1994) Protection against lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 370: 218-220
59. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumor-necrosis factor-a from cells. Nature 385: 729-733
60. Moss ML, Jin S-LC, Milla ME, Burkhart W, Carter HL, Chen W-J, Clay WC, Didsbury JR, Hassler D, Hoffmann CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Becherer JD (1997) Cloning of a disintegrin melalloproteinase that processes precursor tumor necrosis factor-a. Nature 385: 733-736
61. Storch MK, Piddlesden S, Haltia M, livanainen M, Morgan P, Lassmann H (1998) Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination. Ann Neurol 43: 465-471
62. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA (1996) Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 16: 5095-5105
63. Windebank AJ, Wood P, Bunge RP, Dyck PJ (1985) Myelination determines the caliber of dorsal root ganglion neurons in culture. J Neurosci 5: 1563-1569
64. Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12: 295-302
65. Narayana PA, Doyle TJ, Lai D, Wolinsky JS (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43: 56-71
66. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, Antel JP, Matthews PM, Arnold DL (1997) Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 41: 385-391
67. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119: 2009-2019
68. Trapp BD, Ransohoff RM, Fisher E, Rudick RA (1999) Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5: 48-57
69. Link H (1998) The cytokine storm in multiple sclerosis. Mult Scler 4: 12-15
70. Kiefer R, Schweitzer T, Jung S, Toyka KV, Hartung HP (1998) Sequential expression of transforming growth factor-beta 1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation. J Neuropathol Exp Neurol 57: 385-395
71. Brosnan CF, Cannella B, Battistini L, Raine CS (1995) Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45: S16-S21
72. Martino G, Grohovaz F, Brambilla E, Codazzi F, Consiglio A, Clementi E, Filippi M, Comi G, Grimaldi LME (1998) Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. Ann Neurol 43: 340-349
73. Farrell MA, Kaufmann JC, Gilbert JJ, Noseworthy JH, Armstrong HA, Ebers GC (1985) Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation. Neurology 35: 212-218
74. Linnington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130: 443-454
75. Steinman L (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85: 299-302
76. Archelos JJ, Trotter J, Previtali S, Weißbrich B, Toyka KV, Hartung HP (1998) Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol 43: 15-24
77. Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L, Warren KG (1997) Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2 restricted T cell clones from multiple sclerosis patients: identity of key contact residues in the B-cell and T-cell epitopes. J Clinical Invest 100: 1114-1122
78. Noseworthy JH, Gold R, Hartung HP (1999) Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 12: 279-293
79. Hohlfeld R (1997) Immunotherapeutic strategies. In: Zhang J, Hafler D, Hohlfeld R, Miller A (eds) Immunotherapy in neuroimmunologic diseases. Dunitz, London, pp 197-213
80. Ben-Nun A, Wekerle H, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292: 60-61
81. Sloan-Lancaster J, Allen PM (1996) Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 14: 1-27
82. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397-405
83. Aharoni R, Teitelbaum D, Arnon R, Sela M (1999) Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 96: 634-639
84. Archelos JJ, Hartung HP (1997) The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol Med Today 3: 310-321
85. Karpus WJ, Kennedy KJ (1997) MIP-1alpha and MCP-I differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 62: 681-687
86. Youssef S, Wildbaum G, Maor G, Lanir N, Gour-Lavie A, Grabie N, Karin N (1998) Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 161: 3870-3879
87. Clements JM, Cossins JA, Wells GMA, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJH, Miller KM (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-a inhibitor. J Neuroimmunol 74: 85-94
88. Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40: 846-852
89. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Wiliams G, Yong VW (1996) Interferon b-1b decreases the migration of T lymphocytes in vitro: effects on matrix-metalloprotcinase-9. Ann Neurol 40: 853-863
90. Kieseier BC, Seifert T, Giovannoni G, Hartung HP (1999) Matrix metalloproteinases in inflammatory demyelination. Targets for treatment. Neurology 53: 20-25
91. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CCA (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Medicine 4: 78-83
92. Weiner HL, Friedman A, Miller A, Khoury SJ, al Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA (1994) Oral tolerance: immunologie mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Imrnunol 12: 809-837
93. Chen Y, Inobe J, Kuchroo VK, Baron JL, Janeway CA Jr, Weiner-HL (1996) Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 93: 388-391
94. Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51: 682-689
95. Storch M, Lassmann H (1997) Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 10: 186-192